Document Detail


Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data.
MedLine Citation:
PMID:  22242803     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Introduction: Insulin lispro protamine suspension (ILPS) is a protamine-based insulin lispro formulation that allows 24-h coverage while limiting the number of daily injections. ILPS was developed to be the basal insulin component of premixed biphasic formulations with insulin lispro, i.e., the lispro/ILPS 25/75 and 50/50 mixed compounds, but has recently also been marketed as a basal insulin analog formulation, with an indication for the therapy of diabetic patients. Areas covered: This article reviews the available literature on pharmacokinetics/pharmacodynamics (PK/PD), efficacy and safety of ILPS administered as basal insulin, or in premixed biphasic formulations, in patients with type 1 and type 2 diabetes mellitus. Expert opinion: The results of this review suggest that ILPS may be associated with a favorable time-action profile, basal and postprandial glycemic control, and efficacy in terms of rates of patients reaching glycosylated hemoglobin targets; an increased risk of hypoglycemic episodes, compared to other basal insulins, seems to be related to the percentage of patients upgrading from once- to twice-daily injections. This increased risk might be linked with the concomitant use of insulin secretagogues in patients on higher daily dosages and is generally not observed in patients using one injection of ILPS a day. Thus, ILPS can be considered a valid option both as basal insulin and as basal component of the actual premixed formulations of lispro for the therapy of diabetic patients.
Authors:
Antonio Ceriello; Francesco Cremasco; Ester Romoli; Andrea Rossi; Raffaella Gentilella
Related Documents :
21282343 - Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up.
8984173 - In vitro maturation of buffalo oocytes: role of insulin and its interaction with gonado...
22181073 - Cyanidin-3-glucoside-rich extract from chinese bayberry fruit protects pancreatic β ce...
Publication Detail:
Type:  Journal Article     Date:  2012-01-13
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  255-81     Citation Subset:  IM    
Affiliation:
Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Calle Mallorca 183, Piso P01, 08036 Barcelona , Spain +34 93 227 54 00 ext. 4390 ; +34 93 227 92 40 ; aceriell@clinic.ub.es.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A multiparametric analysis of the intrinsically disordered proteins: Looking at intrinsic disorder t...
Next Document:  Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: Systemat...